FLT3 and acute myeloid leukemia: The addition of the multi-kinase inhibitor midostaurin [7] to standard chemotherapy in newly diagnosed FLT3-mutated (FLT3mut) AML significantly improved event-free survival and overall survival in all FLT3 mutation subtypes [8].